Supriya Lifescience

On standalone basis

Quarter ended March 2025 compared with Quarter ended March 2024.

Net sales (including other operating income) of Supriya Lifescience has increased 16.39% to Rs 184.11 crore.''Operating profit margin has jumped from 35.08% to 36.71%, leading to 21.79% rise in operating profit to Rs 67.58 crore.''Raw material cost as a % of total sales (net of stock adjustments) increased from 32.62% to 43.99%. ''Employee cost decreased from 11.56% to 9.09%. ''Other expenses fell from 18.39% to 17.65%. ''

Other income up 36.07% to Rs 2.98 crore.''PBIDT rose 22.33% to Rs 70.56 crore.''Provision for interest fell 30% to Rs 0.42 crore.''Loan funds declined from Rs 5.49 crore as of 31 March 2024 to Rs 5.38 crore as of 31 March 2025.''Inventories rose to Rs 118.35 crore as of 31 March 2025 from Rs 85.25 crore as of 31 March 2024.''Sundry debtors were higher at Rs 134.36 crore as of 31 March 2025 compared to Rs 111.68 crore as of 31 March 2024.''Cash and bank balance rose to Rs 79.15 crore as of 31 March 2025 from Rs 74.96 crore as of 31 March 2024.''Investments declined from Rs 63.80 crore as of 31 March 2024 to Rs 63.24 crore as of 31 March 2025.''

PBDT rose 22.88% to Rs 70.14 crore.''Provision for depreciation rose 55.50% to Rs 6.08 crore.''Fixed assets increased to Rs 599.49 crore as of 31 March 2025 from Rs 457.30 crore as of 31 March 2024.''Intangible assets declined from Rs 1.66 crore to Rs 1.39 crore.''

Profit before tax grew 20.48% to Rs 64.06 crore.''Provision for tax was expense of Rs 13.68 crore, compared to Rs 16.24 crore.''Effective tax rate was 21.35% compared to 30.54%.

Profit after tax rose 36.42% to Rs 50.38 crore.''

Equity capital stood at Rs 16.10 crore as of 31 March 2025 to Rs 16.10 crore as of 31 March 2024.''Per share face Value remained same at Rs 2.00.''

Promoters' stake was 68.30% as of 31 March 2025 ,compared to 68.30% as of 31 March 2024 .''

Full year results analysis

Net sales (including other operating income) of Supriya Lifescience has increased 22.11% to Rs 696.49 crore.''Operating profit margin has jumped from 30.33% to 37.44%, leading to 50.77% rise in operating profit to Rs 260.79 crore.''Raw material cost as a % of total sales (net of stock adjustments) decreased from 35.45% to 32.38%. ''Employee cost decreased from 12.52% to 11.22%. ''Other expenses rose from 20.00% to 20.06%. ''

Other income fell 7.71% to Rs 9.82 crore.''PBIDT rose 47.38% to Rs 270.61 crore.''Provision for interest fell 19.91% to Rs 1.69 crore.''Loan funds declined from Rs 5.49 crore as of 31 March 2024 to Rs 5.38 crore as of 31 March 2025.''Inventories rose to Rs 118.35 crore as of 31 March 2025 from Rs 85.25 crore as of 31 March 2024.''Sundry debtors were higher at Rs 134.36 crore as of 31 March 2025 compared to Rs 111.68 crore as of 31 March 2024.''Cash and bank balance rose to Rs 79.15 crore as of 31 March 2025 from Rs 74.96 crore as of 31 March 2024.''Investments declined from Rs 63.80 crore as of 31 March 2024 to Rs 63.24 crore as of 31 March 2025.''

PBDT rose 48.17% to Rs 268.92 crore.''Provision for depreciation rose 29.29% to Rs 20.44 crore.''Fixed assets increased to Rs 599.49 crore as of 31 March 2025 from Rs 457.30 crore as of 31 March 2024.''Intangible assets declined from Rs 1.66 crore to Rs 1.39 crore.''

Profit before tax grew 49.97% to Rs 248.48 crore.''Provision for tax was expense of Rs 60.52 crore, compared to Rs 46.58 crore.''Effective tax rate was 24.36% compared to 28.11%.

Profit after tax rose 57.80% to Rs 187.96 crore.''

Equity capital stood at Rs 16.10 crore as of 31 March 2025 to Rs 16.10 crore as of 31 March 2024.''Per share face Value remained same at Rs 2.00.''

Promoters' stake was 68.30% as of 31 March 2025 ,compared to 68.30% as of 31 March 2024 .''

Cash flow from operating activities increased to Rs 164.68 crore for year ended March 2025 from Rs 113.31 crore for year ended March 2024.''Cash flow used in acquiring fixed assets during the year ended March 2025 stood at Rs 162.38 crore, compared to Rs 145.66 crore during the year ended March 2024.''

Other Highlights

In Q4 FY25, Asia contributed 30% to total revenue, Europe 36%, LATM 26%, North America 2% and others 6%.

In FY25, Asia contributed 33% to total revenue, Europe 37%, LATM 22%, North America 3% and others 5%.

The Board recommends a final dividend of Re 1 per equity share, with a face value of Rs 2 each, for FY25.

In FY25, in terms of therapy wise contribution, Anesthetic contributed 49% to revenue, Analgesic 8%, Anti-histamine 11%, Vitamins 11%, Anti-Asthmatic 7%, Anti-allergic 4% and Anti-hypertensive 3%.

Supriya Lifescience : Standalone Results

Quarter ended Year ended Particulars 202503 202403 Var.(%) 202503 202403 Var.(%) Net Sales (including other operating income) 184.11 158.18 16.39 696.49 570.37 22.11 OPM (%) 36.71 35.08 163 bps 37.44 30.33 712 bps OP 67.58 55.49 21.79 260.79 172.97 50.77 Other Inc. 2.98 2.19 36.07 9.82 10.64 -7.71 PBIDT 70.56 57.68 22.33 270.61 183.61 47.38 Interest 0.42 0.6 -30.00 1.69 2.11 -19.91 PBDT 70.14 57.08 22.88 268.92 181.50 48.17 Depreciation 6.08 3.91 55.50 20.44 15.81 29.29 PBT 64.06 53.17 20.48 248.48 165.69 49.97 PBT before EO 64.06 53.17 20.48 248.48 165.69 49.97 EO Income 0 0 - 0 0 - PBT after EO 64.06 53.17 20.48 248.48 165.69 49.97 Taxation 13.68 16.24 -15.76 60.52 46.58 29.93 PAT 50.38 36.93 36.42 187.96 119.11 57.80 P/(L) from discontinued operations net of tax 0 0 - 0 0 - Net profit after discontinued operations 50.38 36.93 36.42 187.96 119.11 57.80 EPS (Rs)* 6.26 4.59 36.42 23.35 14.80 57.80 * EPS is on current equity of Rs 16.10 crore, Face value of Rs 2, Excluding extraordinary items. # EPS is not annualised bps : Basis points EO : Extraordinary items Figures in Rs crore Source: Capitaline Corporate Database